Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 17f, No. 3 Park Street, Nangang District, Taipei,shanghai,taiwan, Province Of China
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- elixiron.com
- Keywords
- ImmunAdd Inc..
- HQ
- Taipei, Shanghai
Elixiron Immunotherapeutics Questions
Elixiron Immunotherapeutics's website is elixiron.com
Elixiron Immunotherapeutics's LinkedIn profile is https://tw.linkedin.com/company/elixiron-immunotherapeutics
Elixiron Immunotherapeutics has
20 employees.
View email and phone details for 20
employees at Elixiron Immunotherapeutics.
Elixiron Immunotherapeutics's industry is
Biotechnology Research
Elixiron Immunotherapeutics's top competitors are
Elixirion-Mc,
Braxx Biotech Co., Ltd.,
Steminent Biotherapeutics,
Immunadd Inc.,
Mestag Therapeutics,
Pharmaessentia,
Bonraybio,
Elixironline,
Atamyo Therapeutics,
Syngen Biotech.
Elixiron Immunotherapeutics's categories are Biotechnology Research
Elixiron Immunotherapeutics's founding year is 2017
